09:50 AM - Trillium Therapeutics Inc. : Announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of $5.00 U.S. per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of $5.00 U.S. per share. Trillium Therapeutics Inc.
shares T.TRIL are trading down $0.40 at $6.94.
